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Purpose: Radiation pneumonitis (RP) is one of the most severe toxicities experienced
by patients with breast cancer after radiotherapy (RT). RT fractionation schemes and
techniques for breast cancer have undergone numerous changes over the past decades.
This study aimed to investigate the incidence of RP as a function of such changes in
patients with breast cancer undergoing RT and to identify dosimetric markers that predict
the risk of this adverse event.
Methods and Materials: We identified 1,847 women with breast cancer who received
adjuvant RT at our institution between 2015 and 2017. The RT technique was individually
tailored based on each patient’s clinicopathological features. Deep inspiration breath hold
technique or prone positioning were used for patients who underwent left whole-breast
irradiation for cardiac sparing, while those requiring regional lymph node irradiation
underwent volumetric-modulated arc therapy (VMAT).
Results: Of 1,847 patients who received RT, 21.2% received the conventional dose
scheme, while 78.8% received the hypofractionated dose scheme (mostly 40Gy in
15 fractions). The median follow-up period was 14.5 months, and the overall RP rate
was 2.1%. The irradiated organ at risk was corrected concerning biologically equivalent
dose. The ipsilateral lung V30 in equivalent dose in 2Gy (EQD2) was the most significant
dosimetric factor associated with RP development. Administering RT using VMAT, and
hypofractionated dose scheme significantly reduced ipsilateral lung V30.
Conclusions: Application of new RT techniques and hypofractionated scheme
significantly reduce the ipsilateral lung dose. Our data demonstrated that ipsilateral lung
V30 in EQD2 is the most relevant dosimetric predictor of RP in patients with breast cancer.
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INTRODUCTION
Radiation pneumonitis (RP) is one of the most severe toxicities
caused by radiotherapy (RT) in patients with breast cancer.
Although sometimes fatal, particularly in elderly patients or
those with medical comorbidities, most symptoms of RP can
be resolved with steroid-based medications. In the era of two-
dimensional conventional RT, the central lung distance, defined
as the distance between the midpoint of the posterior field and
the chest wall, was used as an indicator of RP (1, 2). After the
introduction of treatment planning based on three-dimensional
conformal RT (3D CRT), studies have aimed to identify the
dosimetric parameters of the lung that predict RP following RT
for breast cancer. However, such studies remain inadequate for
clinical utility (3, 4).
There has been an important paradigm shift in RT for
breast cancer over the past 20 years. First, hypofractionated
dose scheme emerged as a new standard treatment for this
disease. Several prospective randomized trials demonstrated
that the hypofractionation RT is non-inferior to conventional
fractionated RTwith respect to treatment outcomes and toxicities
after breast conserving surgery. Although hypofractionation
RT after mastectomy is not standard of care yet, recent
prospective trial has shown non-inferior results compared to
conventional RT (5). More radiation oncologists have adopted
such abbreviated RT methods because of their convenience and
cost-effectiveness (6–9). Along with hypofractionated RT, some
other techniques that have become available include volumetric-
modulated arc therapy (VMAT), deep inspiration breath-hold
(DIBH), and prone positioning.
In this study, we aimed to investigate the incidence of RP
and identify the dosimetric markers that predict the risk of this
adverse effect as a function of changes in hypofractionated dose




We identified patients who underwent adjuvant RT following
surgery for breast cancer at our institution between January
2015 and December 2017 using a prospectively collected registry
(n = 2,130). We excluded patients who had distant metastases
at the time of their diagnosis (n = 42), those who did not visit
at regular follow-up (n = 114), and those who were followed at
other hospitals (n = 127). Finally, 1,847 patients who met the
eligibility criteria were included in our study cohort.We reviewed
the medical charts of all patients to determine the incidence of
RP. This study was approved by the institutional review board of
Severance hospital (4-2018-0663).
Treatment
We performed computed tomography (CT) simulation
(SOMATOM sensation; Siemens, Erlangen, Germany) with 3
mm-thick slices for all patients. For immobilization, patients
positioned their ipsilateral arms in abduction and used a
thermoplastic immobilization system (Type-S; Medtec, Alton,
IA, USA). Per our institutional protocol, the irradiation
technique was optimized for each individual to minimize the
dose to the heart while maximizing target dose homogeneity.
Patients with large, pendulous, or ptotic breasts were placed in
the prone position to avoid skin reactions at the inframammary
fold. For cancer of the left breast, the DIBH technique was
applied to displace the heart from the chest wall, as described
previously (10); patients were instructed to apply the Abches
breathing monitoring device (APEX Medical, Tokyo, Japan)
during DIBH. If the distance between the heart and chest wall
was sufficient to lower the heart dose using DIBH by inflating the
lung volume, we performed RT using the DIBH technique. Due
to the setup uncertainties in prone positioning, we underwent
daily cone beam CT during RT. However, if the heart was not
sufficiently spared by DIBH or if internal mammary node (IMN)
irradiation (IMNI) was required, we performed RT with VMAT
for cardiac sparing.
For 3D CRT, target volumes were delineated based on
palpating breast tissue and adding a margin; the border of the
intact breast and treatment planning for 3D CRT was specified
as described elsewhere (11). Regional lymph node irradiation
(RNI), including that of the internal mammary, axillary, and
supraclavicular lymph nodes, was recommended to patients with
metastatic nodes or those with high-risk N0 breast cancer (i.e.,
tumor sizes larger than 2 cm, high-grade tumors, and estrogen
receptor-negative tumors) based on two large scale randomized
trials (12, 13). The partial wide tangent field technique was used
to cover the entire breast as well as the IMNs. The supraclavicular
and axillary lymph nodes were irradiated using a separate beam
that did not overlap with that of the breast field. In patients
who had undergone mastectomy, the chest wall and regional
nodes were irradiated using the reverse hockey stick technique
as described elsewhere (14). Since June 2015, we performed
hypofractionation in patients who received mastectomy.
For VMAT, target volumes and organs at risk were contoured
based on European Society for Radiotherapy and Oncology
guidelines, which was validated using both single-center and
multi-center datasets in Korea (15). For patients with T4
stage or N2-N3 stage, we followed the Radiation Therapy
Oncology Group breast cancer target guidelines. For VMAT
planning, two partial arcs were used limiting the unnecessary arc
segments without compromising dose quality. Plan generation
and dose calculation were performed using the RayStation
treatment planning system (version 5.0, RaySearch, Stockholm,
Sweden). For treatment, 6MV photon beams emitted from a
linear accelerator (Versa HD, Elekta, Stockholm, Sweden) were
used. The 95% isodose encompassed the entire planning target
volume, and volumes in target areas receiving over 107% of
the prescribed dose were minimized. The planning requirements
for organ at risk were as follows: ipsilateral lung V5 <50%,
V10 <35%, V20 <20% (Vχ defined as the percentage of the
total volume exceeding χ Gy), mean heart dose <3Gy, mean
left coronary artery dose <6Gy (maximum point dose [Dmax]
<10Gy), mean contralateral breast dose<2Gy, esophagus Dmax
<12Gy, and mean thyroid dose <3Gy. We concerned the
esophagus and thyroid to reduce radiation induced esophagitis
and hypothyroidism. Cone-beam CT images were obtained daily
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TABLE 1 | Patient characteristics and treatment characteristics.
CF group HF group
No. of patients % No. of patients % No. of patients % p
Age (Year) 0.41
<51 908 49.2% 200 51.0% 708 48.7%
≥51 939 50.8% 192 49.0% 747 51.3%
Pathology
Ductal carcinoma in situ 254 14.1% 59 15.1% 195 13.4% 0.56
Invasive ductal carcinoma 1,327 71.7% 283 72.2% 1,044 71.8%
Invasive lobular carcinoma 85 4.6% 12 3.1% 71 4.9%
Mucinous carcinoma 36 1.9% 15 3.8% 21 1.4%
Tubular carcinoma 43 2.3% 10 2.6% 33 2.3%
Stage 0.08
0 261 14.5% 55 14.0% 206 14.2%
I 740 40.1% 171 43.6% 569 39.1%
II 592 31.8% 110 28.1% 482 33.1%
III 253 13.6% 56 14.3% 197 13.5%
Surgery 0.01
Breast conserving mastectomy 1,485 80.4% 297 75.8% 1,188 81.6%
Mastectomy 362 19.6% 95 24.2% 267 18.4%
Lung disease* 0.94
Yes 9 0.5% 2 0.5% 7 0.5%
No 1,838 99.5% 390 99.5% 1,488 99.5%
Smoking history 0.45
Yes 73 4.2% 13 3.5% 60 4.4%
No 1,728 95.8% 358 96.5% 1,370 95.6%
Regional LN irradiation 0.08
Yes (SCL+IMN+AXL) 712 38.5% 166 42.3% 546 37.5%
No 1135 61.5% 226 57.7% 909 62.5%
Chemotherapy 0.52
Yes
Neoadjuvant CTx 402 21.8% 89 22.7% 313 21.5%
Adjuvant CTx 557 30.2% 109 27.8% 448 30.8%
No 888 48.1% 194 49.5% 694 47.7%
Hormone therapy 0.73
Yes 1,297 70.2% 278 70.9% 1,019 70.0%
No 550 29.8% 114 29.1% 436 30.0%
RT technique <0.001
Free-breathing 1,258 68.1%
FIF 226 12.2% 11 2.8% 215 14.8%
Wedge 194 10.5% 178 45.4% 16 1.1%
RHT 13 0.7% 13 3.3% 0 0.0%
VMAT 825 44.7% 8 2.0% 817 56.2%
DIBH 488 26.4%
FIF 322 17.4% 22 5.6% 300 20.6%
Wedge 164 8.9% 153 39.0% 11 0.8%
RHT 2 0.1% 2 0.5% 0 0.0%
Prone 101 5.5%
FIF 97 5.3% 4 1.0% 93 6.4%
Wedge 4 0.2% 1 0.3% 3 0.2%
*COPD, ILD were included.
CF, Conventional fractionation; HF, Hypofractionation; SCL, Supraclavicular lymph node; IMN, Internal mammary lymph node; AXL, Axillary lymph node; CTx, Chemotherapy; FIF, Field
in field; RHT, Reverse hockey stick; VMAT, Volumetric-modulated arc therapy; BCS, Breast-conserving surgery.
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to verify appropriate patient set-up and minimize positioning
errors. During the study period, three different fractionation
schedules were used: either 40.05Gy in 15 fractions (n = 1,055,
57.1%), or 42.56Gy in 16 fractions (n = 400, 21.7%) for
hypofractionation and 50.4Gy in 28 fractions (n = 392, 21.2%)
schedule for conventional fractionation.
For tumor bed boost, 9 Gy in 5 fractions was applied
in conventional fractionation (n = 297, 20.8%). The tumor
bed boost in hypofractionated RT differed depending on
RT modalities. In case that patients received RT using 3D
CRT in hypofractionation, 10Gy in 5 fractions was applied
(n = 541, 37.9%). The electron beams were used for boost
with 3D CRT. For patients treated by VMAT, the tumor bed
boost was performed using simultaneous integrated boost. The
simultaneous integrated boost dose was determined based on
RTOG 1005 protocol. Total dose of 48Gy in 15 fractions was
applied to tumor bed while total dose of 40.05Gy in 15 fractions
was given to the whole breast or whole breast plus regional LN
(n= 373, 26.2%).
Analysis
The primary endpoint was the occurrence of symptomatic RP,
defined as respiratory symptoms (e.g., dyspnea, non-productive
cough) with correlated radiologic images (e.g., chest radiography
and CT). The RP was graded using common terminology criteria
for adverse events version 5.0. Radiation oncologists prescribed
oral prednisolone until symptoms were relieved. To evaluate the
factors affecting the occurrence of RP, univariate andmultivariate
analyses using Cox proportional hazardsmodels were performed.
In multivariate analysis, the factors significant (p < 0.05) in
univariate analysis were used. The factors related to RP in
other studies were also included for multivariate analsysis. The
receiver operating characteristic (ROC) and area under the curve
analyses were used to identify the optimal cutoff values that
best predict the occurrence of RP. The comparison between
hypofractionation group and conventional fractionation group
was performed using chi-squared test. The logistic regression
analysis was used to evaluate the factors associated with the lung
dose parameters.
For dosimetric analysis, the planning data of all the
patients were transferred into the MIM software (version
6.7.14; Cleveland, OH, USA) for multiple-plan comparison. To
analyze the ipsilateral lung dose parameter, we collected the
ipsilateral mean lung dose, V5, V10, V15, V20, V30, and V40. The
ipsilateral lung dose parameters were converted into equivalent
dose in 2Gy (EQD2) with α/β ratio of 3Gy to correct for
hypofractionation. All tests were conducted by using either the
SPSS software version 20.0 (IBM Corp., Armonk, New York,
USA) or R version 3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria).
TABLE 2 | Comparison of lung dose parameter depending on internal mammary node irradiation and radiotherapy technique.
IMN (–) IMN (+)
Free-breathing
3D CRT
DIBH 3D CRT Prone 3D
CRT
Volumetric arc therapy Free-breathing 3D CRT DIBH 3D CRT Volumetric arc
therapy
No. of patients 307 304 101 423 130 184 398
Mean lung dose
Median 6.50 5.71 1.16 5.70 16.24 11.20 7.56
IQR 4.64–8.32 4.30–8.22 0.52–2.51 4.92–6.76 11.24–19.82 8.9–15.24 6.73–8.33
V5
Median 22.17 21.01 4.03 26.99 54.11 41.30 34.62
IQR 16.54–30.7 15.9–30.00 0.88–8.05 22.92–31.14 43.32–62.21 35.67–51.58 30.91–38.28
V10
Median 17.34 15.60 2.47 17.24 44.83 33.75 23.49
IQR 12.81–21.54 12.38–21.2 0.33–6.00 14.50–20.40 32.74–51.04 27.95–41.18 20.75–26.55
V15
Median 14.79 13.07 1.77 12.00 40.09 30.10 17.76
IQR 10.94–18.42 10.15–17.88 0.17–4.54 9.95–15.08 27.91–45.49 23.19–37.02 15.40–20.08
V20
Median 12.86 11.20 1.35 8.54 36.35 27.13 13.33
IQR 9.38–16.42 8.38–15.78 0.07–3.74 6.69–11.25 24.80–42.00 19.70–33.69 11.19–15.30
V30
Median 9.59 7.85 0.66 3.60 29.02 18.26 6.30
IQR 6.33–13.09 5.19–12.08 0.00–2.00 2.10–5.62 15.00–35.34 11.25–24.62 4.37–8.45
V40
Median 3.26 1.85 0.03 0.36 14.00 2.95 1.13
IQR 0.83–8.56 0.18–7.23 0.00–0.37 0.05–1.16 2.10–22.43 0.87–11.70 0.60–2.14
IMN, Internal mammary lymph node; 3D CRT, 3-Dimensional conformal radiation therapy; DIBH, Deep inspiration breath-hold; VMAT, Volumetric-modulated arc therapy; IQR,
Interquartile range.
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RESULTS
Patient Characteristics
The patient and tumor characteristics are summarized inTable 1.
Approximately 85% of the patients had early breast cancer
(stages 0–2). In total, 38.5% received RNI and 51.9% received
either neoadjuvant or adjuvant chemotherapy. Adjuvant RT was
performed either via the conventional dose scheme (21.2%) or
the hypofractionated dose scheme (78.8%); 44.7% of patients
underwent adjuvant RT using VMAT.
We also compared the patient and tumor characteristics
between the conventional fractionation group and
hypofractionation group (Table 1). Most of the variables
were well-balanced between two groups except for the method
of surgery and the techniques used for RT. More patients in
the hypofractionated group received breast conserving surgery.
Also, most of the patients treated with VMAT underwent
hypofractionated RT.
RP Incidence
RP occurred in 40 patients (2.1%) within a median follow-up
period of 14.5 months. The commonest symptom was a mild
dry cough; few patients also experienced other symptoms such
as shortness of breath. Patients experiencing RP symptoms were
prescribed steroids, following which these symptoms resolved.
None of the patients developed RP grade ≥3. Symptomatic RP
FIGURE 1 | Comparison of lung dose according to the radiotherapy modality without (A) and with (B) internal mammary lymph node irradiation. 3D CRT,
three-dimensional conformal radiotherapy; DIBH, deep inspiration breath hold; Vχ , percentage of the total volume exceeding χ Gy.
FIGURE 2 | Comparison of the lung dose-volume histogram between patients who developed radiation pneumonitis and those who did not.
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FIGURE 3 | Occurrence of radiation pneumonitis according to subgroups with V30 >10% and V30≤10%.
FIGURE 4 | Receiver operating characteristic curve analysis for the optimal
cutoff value to predict the occurrence of radiation pneumonitis. MLD, mean
lung dose; Vχ , percentage of the total volume exceeding χ Gy.
occurred no sooner than 3 months and no later than 12 months
after commencing RT.
Comparison of Lung Dosimetry
The lung dosing parameters when using different RT techniques
(i.e., free-breathing 3D-CRT, DIBH 3D-CRT, prone positioning
RT, and VMAT) were compared (Table 2). Patients who
underwent IMNI had higher doses to the lung than those who
did not. The DIBH technique produced lower lung doses than the
free-breathing technique especially when IMNI was performed.
Among the various techniques, the lung doses in patients who
used prone positioning techniques were significantly lower than
that in patients using other techniques. In patients who did
not undergo IMNI, the lung V30 and V40 were significantly
lower in patients undergoing VMAT than in those in patients
undergoing other techniques, while the lung V5 was higher in
patients undergoing VMAT (Figure 1A). For patients who did
undergo IMNI, the VMAT group showed the lowest mean lung
dose (Figure 1B).
Moreover, we found that patients with RP showed higher
dose-volume histogram parameter values in all areas than those
without RP. Among these individual parameters, ipsilateral lung
V30 showed the largest difference between these two patient
groups (Figure 2).
RPA
We performed RPA to determine the factors associated with
RP. Among various dosimetric parameters, the ipsilateral lung
V30 in EQD2 >10% was associated with significantly higher RP
rates than those of ipsilateral lung V30 in EQD2 ≤ 10%. The RP
occurred in 4.6% in patients with ipsilateral lung V30 more than
10% while only 1.4% of patients experienced RP when ipsilateral
lung V30 was <10% (Figure 3).
Dosimetric Analysis
The mean lung dose, ipsilateral lung V5, V10, V15, V20, V30,
and V40 were all significantly associated with RP. The largest
area under the ROC curve was that of the ipsilateral lung V30
(Figure 4). Univariate analysis showed that hormone treatment,
fractionation schedule, RT technique, and the ipsilateral lung V30
significantly affected RP. On multivariate analysis, patients with
ipsilateral lung V30 larger than 10% had a significantly higher rate
of RP than those with ipsilateral lung V30 <10% (Table 3).
Among the RT techniques, fractionation schemes, and IMN
irradiation, VMAT (odds ratio 0.12, 95% CI 0.08–0.17) was a
major determinant of lowering ipsilateral lung V30 followed by
hypofractionation (odds ratio 0.14, 95% CI 0.10–0.19). The IMN
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TABLE 3 | Univariate and multivariate analysis of factors associated with symptomatic radiation pneumonitis.
Univariate analysis Multivariate analysis
Radiation pneumonitis rate HR (95% CI) p HR (95% CI) p
Age (≥51 vs. <51) 1.8 vs. 2.5% 0.69 (0.37–1.29) 0.25
Lung disease (Yes vs. No) 11.1 vs. 2.1% 5.41 (0.74–39.45) 0.09 5.90 (0.79–43.55) 0.082
Smoking history (Yes vs. No) 0 vs. 2.1% 0.05 (0.00–86.13) 0.42
Chemotherapy (Yes vs. No) 1.9 vs. 2.5% 0.90 (0.63–1.29) 0.58
Chemotherapy regimen 0.09
Taxane based vs. Adriamycin based 1.1 vs. 2.4% 0.52 (0.15–1.88) 0.32
Herceptin based vs. Adriamycin based 6 vs. 2.4% 2.06 (0.83–5.13) 0.12
Hormone therapy (Yes vs. No) 1.7 vs. 3.3% 0.50 (0.27–0.94) 0.03 0.53 (0.28–1.01) 0.053
Regional LN irradiation (Yes vs. No) 2.4 vs. 2.0% 1.12 (0.59–2.09) 0.73
Fraction schedule (Hypofractionation vs. Conventional fractionation) 1.5 vs. 4.6% 0.43 (0.23–0.80) <0.01 0.63 (0.31–1.28) 0.203
Ipsilateral lung dose (V30 > 10% vs. V30 ≤ 10%) 4.6 vs. 1.4% 2.93 (1.53–5.62) <0.01 2.89 (1.51–5.54) 0.002
RT technique 0.007
DIBH 3D CRT vs. Free-breathing 3D CRT 2.5 vs. 5.0% 0.47 (0.23–0.95) 0.04
Prone 3D CRT vs. Free-breathing 3D CRT 0 vs. 5.0% NR
VMAT vs. Free-breathing 3D CRT 0.7 vs. 5.0% 0.22 (0.09–0.55) 0.001
CI, Confidence interval; HR, Hazard ratio; LN, Lymph node; 3D CRT, 3-dimensional conformal radiotherapy; DIBH, Deep inspiration breath hold; VMAT, Volumetric modulated arc therapy;
NR, Not reported.
TABLE 4 | Analysis the factor determining the lung V30.
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
IMN irradiation (Yes vs. No) 2.63 (2.15–3.22) <.001 6.59 (4.88–8.92) <.001
Hypofractionation (Yes vs. No) 0.07 (0.06–0.10) <.001 0.14 (0.10–0.19) <.001
VMAT (Yes vs. No) 0.12 (0.10–0.16) <.001 0.12 (0.08–0.17) <.001
Prone (Yes vs. No) NR NR
DIBH (Yes vs. No) 0.30 (0.24–0.38) <.001 0.98 (0.73–1.33) 0.911
OR, Odds ratio; CI, Confidence interval; IMN, Internal mammary node; VMAT, Volumetric modulated arc therapy; DIBH, Deep inspiration breath hold; NR, Not reported.
irradiation was the only factor increasing the ipsilateral lung V30
(odds ratio 6.59, 95% CI 4.88–8.92) (Table 4).
DISCUSSION
This study investigated the incidence of RP in patients with breast
cancer who underwent conventional and hypofractionation RT
and identified dosimetric markers that predict the risk of RP. We
demonstrated that ipsilateral lung V30 is the dosimetric predictor
of RP that is the most relevant in patients with breast cancer. The
change in RT techniques using VMAT and hypofractionation
dose schemes reduce the ipsilateral lung V30.
Several studies have shown that the occurrence of RP is
affected by both patient-related and treatment-related factors.
Patient-related factors that affect the incidence of RP include
existing lung disease, poor pulmonary function, and smoking
history (16, 17). Meanwhile, treatment-related factors known
to affect RP development in patients with lung cancer include
radiation dose, irradiated lung volume, schedule of fractionation,
and usage of chemotherapy (18–21). However, as patients with
breast cancer tend not to have underlying lung diseases or
smoking histories with the same frequencies as those with
lung cancer, our study revealed no association between patient-
related factors and the occurrence of RP. However, treatment-
related factors, particularly those related to RT, did affect RP
development, as reported previously (11).
In this study, we showed that the hypofractionation dose
scheme lowered the ipsilateral lung dose V30. It was suggested
that the α/β ratio for breast tissue ranges from 3 to 4Gy,
which is similar to that of normal tissues (6), and this was later
confirmed in the START A, START B, and another Canadian
study (8, 22, 23). Hence, hypofractionation has become the
standard treatment for breast cancer. While hypofractionation
did not significantly affect RP development in our study, the V30
of the ipsilateral lung were found to be strong predictors of RP.
We also demonstrated that advances in RT techniques have
reduced the incidence rate of RP. Improvements that were
designed to reduce the dose to the heart while maintaining
RT safety and efficacy include intensity-modulated RT (IMRT),
DIBH, and prone positioning; these techniques also significantly
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decreased the dose to the lung by more than 50%. The DIBH can
lower the dose to the heart, but the coverage of the ipsilateral
whole breast planning target volume can be suboptimal. In case
that the tumor was located at medial location of the breast,
tangent fields are difficult to fully cover tumor bed and avoid
the heart simultaneously. Even though the prone positioning for
breast enables lowering the dose to the lung and heart, but setup
uncertainties exist for prone positioning (24). By contrast, IMRT
made it possible to protect the heart and ipsilateral lung without
compromising target coverage and set up uncertainties.
Because landmark studies such as the MA 20 and EORTC
22922 trials demonstrated that RNI can reduce the risk of
early breast cancer recurrence (12, 13), radiation oncologists
increasingly consider its application but remain hesitant owing
to the risk of toxicity to the heart and lung. While we perform
DIBH and prone positioning for patients at our hospital who
are not undergoing RNI, 3D CRT with partially wide tangent
fields has been performed in patients requiring RNI, including
IMNI. IMRT for breast cancer is widely used today after it became
reimbursable by the national insurance program in our country
in 2015. Our study showed that IMRT can sufficiently cover the
whole breast and regional lymph nodes, particularly IMNs, while
effectively reducing lung, and heart toxicity.
The chemotherapy regimen did not affect the incidence of
RP in our study. As some chemotherapeutic agents act as
sensitizers to radiation, the patients who received chemotherapy
could be at higher risk to RP. The article showing that
chemotherapy increased the risk of RP demonstrated that
sequential chemotherapy diminished the risk of RP as compared
to concurrent chemoradiotherapy (25). In our study, none of
the patients underwent concurrent chemotherapy during RT. As
sequential chemotherapy has minimal impact on development
of RP, neither the chemotherapy regimen nor the use of
chemotherapy increased the risk of RP in our study.
Sequential tumor bed boost was applied in patients treated
with 3D CRT while simultaneous integrated boost was used in
patients treated with VMAT. In this study, sequential tumor bed
boost dose was not accounted for analysis. However, as electron
beams were used for sequential tumor bed boost in case of
patients treated with 3D CRT, we believed that the effect of tumor
bed boost to the lung dose was negligible.
No significant parameters predicting the occurrence of RP in
patients with breast cancer have been identified to date. The 3D
CRT technique can reduce the areas receiving low irradiation
doses (e.g., the V5 and V10) on the dose-volume histograms
but not the areas receiving high doses. By contrast, the VMAT
technique can reduce the areas of high RT dose while widening
the areas of low irradiation (26). Previous studies in patients with
breast cancer showed that V20 lung constraints could markedly
reduce RP (27, 28). However, our results also demonstrated that
V30 constraints were significantly associated with reduced RP
rates in patients with breast cancer.
Our study was limited by its retrospective design and
single-institution analysis. Some unbalance existed in patient
characteristics between hypofractionated and conventional
fractionated RT group, as the surgical method and RT
techniques were significantly different between two groups.
Also, the number of patients with RNI and without RNI
differ largely. Although most of the factors were well-
balanced between two groups, careful interpretation of results
is needed. As such, external validation is necessary to confirm
our findings.
In conclusion, our study demonstrated that the
hypofractionation dose scheme and RT techniques such as
VMAT can reduce the radiation dose and potentially the
incidence of RP. Although external validation is still required,
we clearly showed that ipsilateral lung V30 in EQD2 is reliable
dosimetric predictors of RP in patients with breast cancer.
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